Juan Valcárcel

Centre de Regulació Genòmica

Life & Medical Sciences

Juan Valcárcel studied biology and chemistry at the Universities of Santiago de Compostela and Autónoma de Madrid. He obtained his PhD in 1990 for work carried out at the Centro de Biología Molecular Severo Ochoa under the supervision of Juan Ortín. He did postdoctoral work in the laboratory of Michael Green at the University of Massachusetts and in 1996 he joined the European Molecular Biology Laboratory in Heidelberg as a group leader. In 2002 his group moved to the Centre de Regulació Genòmica in Barcelona, where he is a senior scientist and ICREA Research Professor. Since the time of his PhD work, his research has focused on how pre-mRNAs are spliced and how this process can be regulated.

Research interests

The genome provides the instructions to build and maintain the function of a living organism. Strangely, in complex organisms these instructions are not written as continuous messages, but rather as smaller pieces interrupted by meaningless text. This arrangement has the advantage that the pieces can be combined in different ways to generate alternative instructions. We study the molecular machinery that puts messages together and how the production of alternative messages is regulated.

Selected publications

- Vigevani L, Gohr A, Webb T, Irimia M & Valcarcel J 2017, 'Molecular basis of differential 3 ' splice site sensitivity to anti-tumor drugs targeting U2 snRNP', Nature Communications, 8, 2100.

- Makowski K, Vigevani L, Albericio F, Valcárcel J* & Álvarez M* 2017, 'Sudemycin K: a synthetic anti-tumor splicing inhibitor variant with improved activity and versatile chemistry', ACS Chemical Biology, vol 12, pp 163 - 173. * Co-corresponding authors.

- Cifdaloz M, Osterloh L, Graña O, Riveir-Flakenbach E, Ximenez-Embrun P, Muñoz J, Tejedo C, Calvo TG, Karras P, Olmeda D, Miñana B, Gómez-López G, Cañón E, Eyras E, Guo H, Kappes F, Ortiz-Romero PL, Rodrigues-Peralto JL, Megías D, Valcárcel J and Soengas MS 2017, 'Systems analysis identify melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1', Nature Communications, 8, 2249.